Zanidatamab (ZW25) 是一种针对 2 个不同 HER2 表位 (ECD2 和 ECD4) 的人源双特异性单克隆抗体。Zanidatamab 具有抗肿瘤活性。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-HER2/neu Reference Antibody (Zanidatamab) is 124.82 kDa.

Anti-HER2/neu Reference Antibody (Zanidatamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-HER2/neu Reference Antibody (Zanidatamab) is 98.25%, determined by SEC-HPLC.

Zanidatamab bound to HER2 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Zanidatamab bound to hu-HER2-his, and the EC50 was 0.012 nM.

Zanidatamab bound to BT474 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Zanidatamab bound to BT474 cells, and the EC50 was 3.061 nM.

Co-incubation of Zanidatamab with BT474 cell and PBMCs for 4 hours, then LDH was detected to evaluate the ADCC activity of Zanidatamab. As shown in fig, Zanidatamab has ADCC activity, and the IC50 was 0.023 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.